2003 Abstracts
COMPARISON OF BREATH-ACTUATED JET NEBULIZER (BAN) IN "CONTINUOUS DELIVERY" MODE WITH OTHER CONTINUOUS DELIVERY NEBULIZERSJolyon P. Mitchell Ph.D, Kimberly J. Wiersema B.A., Cathy C. Doyle B.Sc,
and Mark W. Nagel HB.Sc Trudell Medical Aerosol Laboratory, London, Canada
The AeroEclipse® BAN (Monaghan Medical Corp., Plattsburgh, N.Y.) has been equipped with an optional blue cap whose purpose is to retain the actuator piston in the position it would occupy during inhalation in breath-actuated mode, so that the nebulizer operates continuously. The present study compared the delivery of a bronchodilator from diluted albuterol sulfate respirator solutions (3-ml of 0.83 and 1-ml of 2.5 mg/ml albuterol in physiologically normal saline (0.9% w/v NaCl)), via this nebulizer, the Micromist® (Hudson RCI, Temecula, CA), Misty-NebT (Allegience Healthcare Corp., McGaw Park, IL) and the LCDT (PARI Respiratory Equipment, Monterey, CA). Each nebulizer was tested using a breathing simulator set to the following parameters representative of adult use: tidal volume = 600-ml, rate = 10 breaths/min, inspiratory/expiratory ratio 1:2. The total mass of albuterol (TM) delivered to the first sputter was determined by filter collection at the mouthpiece of the nebulizer operated with compressed air supplied at 50 psig at 8 L/min (n = 5 devices/group, 3 replicates/device). The fraction of the aerosol contained in droplets finer than 4.8 mm aerodynamic diameter (FPF) was determined by laser diffractometry in a parallel study, so that the fine droplet mass (FM) could be calculated as the product of TM and FPF. Values of FM (mean ± SD) and time to deliver medication (Tmed) were as follows:
| Solution (mg/ml) | AeroEclipse® | LCDT | Micromist® | MistyNebT | ||||
| 0.83 | 2.50 | 0.83 | 2.50 | 0.83 | 2.50 | 0.83 | 2.50 | |
| FM (mg) | 360 ± 22 | 263 ± 26 | 149 ± 16 | 108 ± 4 | 209 ± 12 | 15.4 ± 5.9 | 82 ± 9 | 31 ± 5 |
| Tmed (min) | 3 | <1 | 2 | <1 | 7 | <1 | 4 | <1 |
The AeroEclipse® nebulizer delivered significantly more FM in continuous delivery mode than the other nebulizers when operated in continuous mode with either solution strength (1-way repeated measures ANOVA, p <0.05). Tmed from the AeroEclipse® nebulizer was comparable with the best performing continuous nebulizer (LCDT).
Feedback: Respiratory care
